SLC5A2 and dementia: Secnik et al. [18] extracted data from diabetic patients from five Swedish national registers, highlighting that the mortality rate in patients with dementia using metformin (the most prescribed antidiabetic in their cohort) was not different from that of non-users, while the use of SGLT2 inhibitors was associated with a 57% lower mortality rate in new users with dementia.